All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Long-Term Follow-Up Supports Acalabrutinib-Based Regimens in Treatment-Naïve CLL

June 4th 2022

At approximately 5 years of follow-up, findings from the phase 3 ELEVATE-TN study show that treatment outcomes are more favorable with acalabrutinib with or without obinutuzumab compared with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.

BTX-1188 Demonstrates Safety Benefits, Enters Phase 1 Trials in AML and Solid Tumors

June 4th 2022

BTX-1188, a first-in-class oral molecular glue, is undergoing investigation in phase 1 clinical trials in patients with solid tumors or acute myeloid leukemia, after preclinical trials supported its potential safety benefits in this population and demonstrated its high sensitivity in Myc-driven cancer cell lines.

Epcoritamab Plus R-CHOP Shows Efficacy and Tolerability as First-Line Treatment for High-Risk DLBCL

June 4th 2022

The addition of subcutaneous epcoritamab to standard-of-care R-CHOP demonstrated clinically meaningful response in the first-line treatment of patients with high-risk diffuse large B-cell lymphoma according to updated results of a single-arm of the EPCORE NHL-2 trial.

Magrolimab Plus Azacitidine Elicits Manageable Anemia in HR-MDS

June 4th 2022

Magrolimab plus azacitidine, at priming and maintenance doses, enables manageable anemia in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, according to results from a prospective phase 1 study (NCT03248479).

Hyper-CVAD Plus Sequential Blinatumomab With or Without Inotuzumab Elicits Clinical Benefit in Ph-Negative B-Cell ALL

June 4th 2022

Sequential administration of blinatumomab with or without inotuzumab following hyper-CVAD elicited high rates of minimal residual disease negativity and a durable overall survival benefit among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic lymphoma.

Addition of Ivosidenib to Azacitidine Improves Outcomes in Newly Diagnosed IDH1-Mutant AML

June 4th 2022

The combination of ivosidenib and azacitidine elicited a clinically meaningful benefit across end points compared with azacitidine alone among patients with newly diagnosed IDH1-mutant acute myeloid leukemia who were ineligible for intensive induction chemotherapy.

Glofitamab Demonstrates Durable Response in Heavily Pretreated Large B-Cell Lymphoma

June 4th 2022

Glofitamab elicited an objective response rate of 51.6% when administered for a fixed duration among patients with patients with heavily pretreated, highly refractory large B-cell lymphoma, regardless of prior CAR T-cell therapy exposure, according to findings from a phase 2 expansion study.

Sacituzumab Govitecan Demonstrates Significant Clinical Benefit in HR+/HER2- Metastatic Breast Cancer

June 4th 2022

Sacituzumab govitecan elicited a statistically significant and clinically meaningful benefit among patients with hormone receptor–positive, HER2-negative breast cancer with endocrine therapy resistance, reducing the risk of disease progression by 34% vs standard chemotherapy, according to results of the phase 3 TROPiCS-02 trial.

Pacritinib Offers Safe and Tolerable Treatment Option for Patients With Myelofibrosis

June 4th 2022

Treatment with pacritinib demonstrated a comparable safety profile to best available therapies for the treatment of patients with myelofibrosis.

Adjuvant Everolimus Displays RFS Benefit in Very High-Risk RCC

June 4th 2022

Adjuvant everolimus significantly improved recurrence-free survival when compared with placebo in patients with very high-risk renal cell carcinoma.

Atezolizumab Plus Cabozantinib Elicits Clinical Activity in Advanced Urothelial Cancer

June 4th 2022

Cabozantinib plus atezolizumab demonstrated promising clinical activity and a suitable safety profile as first-line therapy in patients with cisplatin- eligible and -ineligible, inoperable locally advanced or metastatic urothelial cancer and as second- or later-line therapy in those who received a prior immune checkpoint inhibitor, according to findings from the phase 1b COSMIC-021 trial.

Single-Agent Cabozantinib Stalls as Maintenance Therapy in Advanced Urothelial Cancer

June 4th 2022

Results of the ATLANTIS study do not support further investigation of cabozantinib alone as a maintenance therapy after platinum-based chemotherapy in unselected patients with advanced urothelial cancer.

Avasopasem Reduces Severe Oral Mucositis In Patients Receiving Chemoradiotherapy for Advanced Head and Neck Cancer

June 4th 2022

Avasopasem significantly reduced severe oral mucositis across all intensity-modulated radiotherapy landmarks in patients with locally advanced, nonmetastatic head and neck cancer.

Frontline Brentuximab Vedotin Plus Chemotherapy Improves 6-Year Survival in Hodgkin Lymphoma

June 3rd 2022

Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine demonstrated a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, with a manageable safety profile consistent with prior findings in patients with previously untreated stage III/IV classical Hodgkin lymphoma.

CLN-081 Produces Antitumor Activity With Acceptable Safety in Heavily Pretreated EGFR Exon 20 Insertion+ NSCLC

June 3rd 2022

The selective EGFR inhibitor CLN-081 elicited objective responses in heavily pretreated patients with non–small cell lung cancer with EGFR exon 20 insertions and was found to have an acceptable toxicity profile, according to data from the phase 1/2a CLN-081-001 trial.

Superior Survival Benefit With Ramucirumab Plus Pembrolizumab Observed in ICI-Resistant NSCLC

June 3rd 2022

The addition of ramucirumab to pembrolizumab elicited significant response among patients with advanced non–small cell lung cancer who experienced disease progression following treatment with PD-1/PD-L1 inhibitors and platinum-based doublet chemotherapy.

Adagrasib Elicits Deep and Durable Responses in Pretreated KRAS G12C–Mutant NSCLC

June 3rd 2022

Adagrasib led to early onset and deep responses translating to encouraging survival as a single agent in previously treated patients with KRAS G12C–mutated non–small cell lung cancer, according to results from cohort A of the phase 1/2 KRYSTAL-1 trial.

Sugemalimab Shows Promise for Natural Killer/T-cell Lymphoma

June 3rd 2022

Treatment with the anti–PD-L1 IgG4 antibody sugemalimab resulted in a response for nearly half of patients and a complete response in one-third of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma.

Ibrutinib Plus Bendamustine and Rituximab Shows PFS Benefit in Older Patients with MCL

June 3rd 2022

Ibrutinib in combination with bendamustine and rituximab with rituximab maintenance elicited a significant improvement in progression-free survival compared with standard chemoimmunotherapy in older patients with mantle cell lymphoma.

American Oncology Network Appoints Stephen “Fred” Divers, MD as Chief Medical Officer

June 3rd 2022

American Oncology Network, LLC, a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in community-based settings is pleased to announce that Stephen “Fred” Divers, MD has been named as the company’s new Chief Medical Officer.